Skip to main content
. 2021 Feb 15;2021(2):CD013109. doi: 10.1002/14651858.CD013109.pub2

Gueiros 2019.

Methods Single‐centre parallel RCT (open label)
Participants PD patients
Interventions Spironolactone
Outcomes Relative and absolute progression of the coronary calcium score; hyperkalaemia; adverse effects (hypotension, hyperpotassaemia, gynaecomastia); mineral metabolism at 12 months; change in inflammation markers at 12 months; causes of study discontinuation
Notes Protocol registration only; recruitment completed, current status is unknown